Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 0.17% 117.00 117.20 117.80 119.80 114.60 115.00 5,333,256 16:35:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 186.1 17.5 6.7 1,243

Ip Share Discussion Threads

Showing 2351 to 2374 of 2550 messages
Chat Pages: 102  101  100  99  98  97  96  95  94  93  92  91  Older
DateSubjectAuthorDiscuss
05/5/2021
08:35
the 195M ONT fundraising is odd. I suspect either they are urgently building another factory (possibly overseas) to meet demand or the flotation will be delayed or maybe they have an acquisition target. Uncertainty over reasons for fundraising seems to have hit IP's share price
wetpantz
05/5/2021
08:33
Monetary flows over ride any news, good or bad. A shift occurring.
p1nkfish
05/5/2021
07:55
Thanks p1nk, Mas. £54m added to NAV
bamboo2
05/5/2021
07:36
5 May 2021 IP Group plc - Portfolio company Kuur Therapeutics Ltd acquired by Nasdaq-listed Athenex Inc for up to $185m (GBP133m*) IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is pleased to announce that portfolio company Kuur Therapeutics Ltd ("Kuur") has been acquired by Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company, for a total potential consideration of $185 million. Under the terms of the agreement, Athenex will pay $70 million (GBP50 million*) upfront to Kuur shareholders and its former employees and directors, comprised primarily of equity in Athenex common stock. Additionally, Kuur shareholders and its former employees and directors are eligible to receive up to $115 million (GBP83 million*) of milestone payments, which may be paid, at Athenex's sole discretion, in either cash or additional Athenex common stock (or a combination of both). As a result, and following conversion of loan-notes made available to Kuur in 2019 and 2020, IP Group will receive GBP30 million* ($42 million) in Athenex stock and is eligible to receive up to a further GBP52 million* ($72 million) in milestone payments in cash or stock. IP Group's holding in Athenex stock will be subject to typical lock-up provisions. The Directors anticipate that the transaction will result in an increase in the Group's net asset value of approximately GBP26 million*. Dr Sam Williams, Managing Partner, IP Group Life Sciences, said: "This is an excellent outcome for Kuur's shareholders, partners and management team. Most importantly, with the backing and support of Athenex, Kuur's pipeline of innovative cell-therapies for the treatment of cancer now has a superb chance of fulfilling its clinical promise. We're particularly proud of what the Kuur management team has been able to achieve since taking over the company a little over a year ago, moving a second product into the clinic, achieving striking clinical response rates and securing a highly satisfactory exit."
bamboo2
05/5/2021
07:34
5 May 2021 IP Group plc - Portfolio company Inivata acquired by Nasdaq-listed NeoGenomics IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that portfolio company Inivata Ltd ("Inivata"), a leader in liquid biopsy, has announced that NeoGenomics, Inc (NASDAQ: NEO. ) has agreed to acquire Inivata. The acquisition follows a $25 million equity investment by NeoGenomics in Inivata in May 2020, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million. As a result, IP Group will receive approximately $91 million (GBP66 million*) in cash or, potentially, NeoGenomics stock, at the Group's election and if certain other conditions are satisfied. The Directors anticipate that the transaction will result in an increase in the Group's net asset value of approximately GBP28 million*. Completion of the transaction is subject to US anti-trust filing. Dr Craig Richardson, Partner, IP Group Life Sciences, and IP Group's representative on the Inivata Board, said: "This is an excellent outcome for Inivata's shareholders and management team. As part of NeoGenomics, Inivata's innovative liquid biopsy products now have a superb chance of fulfilling their full potential and, most importantly, improving the detection and treatment of cancer, thereby improving patients' lives. In addition, this exit represents a very good financial result for IP Group." Inivata will remain a separate business division alongside NeoGenomics' growing clinical, pharma and informatics divisions. Current Inivata CEO Clive Morris will become the President of Inivata and will report to Mark Mallon, CEO of NeoGenomics. * GBP equivalents calculated using 1.39 USD/GBP.
bamboo2
05/5/2021
07:11
2 interesting exits.
p1nkfish
05/5/2021
01:15
Hope that your top-up timing is good bamboo2 ! 👌 It’s time for Nanopore to come to market The Oxford Nanopore flotation, if it ever happens, will be quite a moment. Ministers and City leaders were gushing over the Deliveroo float in March (right until it flopped) and Nanopore is more exciting from a technology point of view. Being able to read the genes of any living tissue on a portable device smaller than a Mars bar opens up a cornucopia of potential customers — in medicine, food production and scientific research. Nanopore not only has pioneered this technology but also is producing the machines in a British factory. Strangely, then, having announced only a month ago plans to float in the second half of this year, it has decided to do another round of private funding first. The £195m raised will surely provide all the cash it needs for at least another few years. Even in 2019, a year of heavy costs, losses were only £72m. The deal is another valuation point. The injection of capital from M&G, Temasek and others values Nanopore at £2.5bn, nicely higher than the last valuation point in 2020 of £1.9bn. Big names such as M&G will help to reassure investors in any flotation later in the year, but, with bags of cash under its belt, Nanopore will need little new capital. The float may be more about providing an exit to investors or a more liquid currency for acquisitions or bonuses. The sooner Nanopore secures a listing, with the accompanying transparency, disclosure and liquidity, the more confident we can be that it really is a potential world-beating gem and not a capital-guzzling fantasy. https://www.thetimes.co.uk/article/it-s-time-for-nanopore-to-come-to-market-xndgz02l2
masurenguy
04/5/2021
17:14
Mas, thanks for the report. For info, ONT at £3.9bn is a NAV of around 65p per IPO share. NAV at end 2020 had ONT valued at 32p per share. ps, added quite a few following the gap fill.
bamboo2
04/5/2021
17:00
If the ONT IPO was valued at £3.9bn then the IPO 14.5% stake would be worth £565m ! M&G has ploughed £35m into Oxford Nanopore Technologies, the former Neil Woodford favourite that is preparing for one of the largest flotations in London this year. The DNA sequencing technology start-up has announced plans to list on the London Stock Exchange in 2021, with Jefferies and Berenberg valuing the initial public offering (IPO) at $5.4bn (£3.9bn). Based on its last financing round more than a year ago, investors latest valuation of the company was £1.9bn, however. Citywire: 5 May 21
masurenguy
04/5/2021
13:52
Gap filled
bamboo2
04/5/2021
08:53
I think there'll be a hell of a lot more than 6% gong on their nano valuation when they next get around to revaluing it, or when it floats.
pierre oreilly
04/5/2021
08:51
Masurenguy - a correction to your post. I believe it should be "£195m" and not "£1953m"
benchmark
04/5/2021
07:48
Mas, thanks. Over 4 months approx 6% added to the ONT valuation.
bamboo2
04/5/2021
07:21
IP Group Portfolio company Oxford Nanopore Technologies raises £195m in new investment IP Group plc, notes that portfolio company Oxford Nanopore Technologies Ltd has raised £195m in new capital including £125m from new investors Temasek, Wellington Management, M&G Investments and Nikon with existing shareholders investing £70m. IP Group committed £18.7m to the round, being its full pre-emptive allocation. Following completion of the round, IP Group has a 14.5% undiluted beneficial stake in Oxford Nanopore, valued at £359m.
masurenguy
02/5/2021
14:31
Gap 6/4/2021 remains unfilled, it measures 126.4-126.6 My chart showing a possible turn 4/5/2021, which I guess if it materialises, will be a low turn. Once it's filled, price should be able to move on.
bamboo2
01/5/2021
17:16
Also mentioned in this article. https://www.standard.co.uk/business/pharmaceuticals/arix-acacia-neil-woodford-biotech-investment-b932706.html
eeza
01/5/2021
17:06
Oxford Nanopore will comprise nearly half of Neil Woodford's new offering from WCM Partners, according to a document sent to potential investors. The WCM Partners Healthcare Portfolio will be composed of eight UK and US healthcare technology businesses, all of which were previously held by Woodford across his old funds. Oxford Nanopore Technologies will comprise almost half of the entire fund, with a 43% weighting, with Viamet and Immunocore the second and third largest holdings at 18% and 12% respectively. According to an email sent as part of an unsolicited approach, the portfolio has "significant pre-interest" and currently stands at £330m. While WCM Partners is registered in the UK, WCM Partners Healthcare, the company name featured on the proposition, is based in the Cayman Islands rather than the originally touted Jersey. hxxps://www.investmentweek.co.uk/news/4030481/oxford-nanopore-represents-half-cayman-woodford-fund
bamboo2
29/4/2021
08:55
do many know much about hinge health? this unicorn has popped up from relatively nowhere. my understanding is there are over 100 holdings in ip stable . i guess there will be say another 2 or 3 unicorns hiding in there too?
edwardt
26/4/2021
09:26
Pierre, in terms of current NAV, allowing for the last quarters uplift in ONT this is probably fairly valued at 134. Obviously there will be a premium added on to the ONT valuation, but this is currently unknown. There are probably also other constituents with improved valuations since end of 2020. My guess is that there are some holders who have bought on the way up taking profits, although the chart does suggest that the stock is still being accumulated. Good to see you become more positive!
bamboo2
26/4/2021
08:51
A little confused at the lack of response to the nano news.Nano is a very big deal for IPO and nowhere near reflected in IPOs price yet. Easy to see this climbing purely on the back of nano as it's float gets nearer.
pierre oreilly
25/4/2021
21:03
Thanks Mas. UK govt is a major ONT customer and the UK Govt need to promote the City as open for business. Hence the London listing.
bamboo2
25/4/2021
13:44
rob, Can you paste the text here?
bamboo2
25/4/2021
12:56
Big positive article on ONT in the Sunday Times business section today. Think it is the start of the IPO pr campaign
robertspc1
21/4/2021
08:09
Gap 6/4/2021 remains unfilled for now. Measures 126.4-126.6
bamboo2
Chat Pages: 102  101  100  99  98  97  96  95  94  93  92  91  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 03:57:39